. . . . . . . "[While crizotinib, a multi-targeted ALK/ROS1/MET tyrosine kinase inhibitor (TKI), has demonstrated significant clinical activity in ROS1-rearranged NSCLC, no companion diagnostic assay has been approved for the detection of ROS1-rearrange NSCLC by the US FDA.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:14:31+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .